DaVita (DVA) Stock Price, News & Analysis

Company Overview

DaVita Inc. is a healthcare company focused on kidney care and renal disease management. Through its DaVita Kidney Care business, the company provides outpatient dialysis treatments for people with end-stage kidney disease, including hemodialysis and peritoneal dialysis, as well as home dialysis support.

The company also operates hospital-based dialysis programs and offers clinical, administrative and care-coordination services intended to support patients across the kidney-care journey. Its services include education, access to care, laboratory support and assistance for patients who may be candidates for kidney transplantation.

DaVita was founded in 1994 as Total Renal Care Holdings and adopted the DaVita name in 2000. Headquartered in Denver, Colorado, the company primarily serves patients in the United States and also has kidney-care operations in selected international markets.

Key Stats

• Today's Range: $177.00 to $180.11
• 50-Day Range: $174.21 to $233.43
• 52-Week Range: $101.00 to $247.49
• Volume: 369,636 shs
• Average Volume: 701,739 shs
• Market Capitalization: $11.42 billion
• P/E Ratio: 14.65
• Dividend Yield: N/A
• Price Target: $233.43
• Consensus Rating: Moderate Buy

DaVita Stock Analysis - MarketRank™

DaVita scored higher than 92% of companies evaluated by MarketBeat, and ranked 31st out of 883 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

DaVita has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on no strong buy ratings, 4 buy ratings, 3 hold ratings, and no sell ratings.

Upside Potential

DaVita has a consensus price target of $233.43, representing about 30.4% upside from its current price of $178.97.

Amount of Analyst Coverage

DaVita has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 4.4 / 5
• Proj. Earnings Growth: 18.39%

Earnings Growth

Earnings for DaVita are expected to grow by 18.39% in the coming year, from $14.57 to $17.25 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of DaVita is 14.65, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.00.

Price to Earnings Ratio vs. Sector

The P/E ratio of DaVita is 14.65, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.15.

Price to Earnings Growth Ratio

DaVita has a PEG Ratio of 0.46. PEG Ratios below 1 indicate that a company could be undervalued.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.23% of the float of DaVita has been sold short.

Short Interest Ratio / Days to Cover

DaVita has a short interest ratio ("days to cover") of 6.5.

Change versus previous month

Short interest in DaVita has recently increased by 19.81%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

DaVita does not currently pay a dividend.

Dividend Growth

DaVita does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.46

News Sentiment

DaVita has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for DaVita this week, compared to 5 articles on an average week.

Search Interest

6 people have searched for DVA on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

MarketBeat Follows

3 people have added DaVita to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, DaVita insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.90% of the stock of DaVita is held by insiders.

Percentage Held by Institutions

90.12% of the stock of DaVita is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/04/2026
• Today: 10/10/2026
• Next Earnings (Estimated): 10/28/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Healthcare Providers & Services
• Sub-Industry: Healthcare Services
• Current Symbol: NYSE:DVA
• CIK: 927066
• Web: www.davita.com
• Phone: (310) 536-2668
• Fax: 302-636-5454
• Employees: 78,000
• Year Founded: 1994

Price Target and Rating

• Average Price Target for DaVita: $233.43
• High Price Target: $270.00
• Low Price Target: $215.00
• Potential Upside/Downside: +30.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.57
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): $12.22
• Trailing P/E Ratio: 14.65
• Forward P/E Ratio: 12.28
• P/E Growth: 0.46
• Net Income: $746.80 million
• Net Margins: 6.05%
• Pretax Margin: 10.48%
• Return on Equity: -217.63%
• Return on Assets: 5.07%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.47
• Quick Ratio: 1.41

Sales & Book Value

• Annual Sales: $13.64 billion
• Price / Sales: 0.84
• Cash Flow: $21.96 per share
• Price / Cash Flow: 8.15
• Book Value: ($5.29) per share
• Price / Book: -33.83

Miscellaneous

• Outstanding Shares: 63,800,000
• Free Float: 62,588,000
• Market Cap: $11.42 billion
• Optionable: Optionable
• Beta: 0.80